Urologic Oncology
Yale Cancer Center is the only National Cancer Institute-designated Comprehensive Cancer Center in Connecticut, and is one of just 49 in the United States. This designation by the National Cancer Institute recognizes Yale’s world class, state-of-the-art programs in multidisciplinary cancer research. Our research efforts are rooted in clinical excellence and our patients benefit from a cutting-edge multidisciplinary approach to treating cancers of the genitourinary tract, including cancers of the prostate, bladder, kidney, ureters, testis, and penis.
Patients of the Prostate and Urologic Cancers Program at Smilow Cancer Hospital benefit from a comprehensive, disease-based, multi-specialty team. Our physicians are recognized experts in urologic oncology (surgery), medical oncology, radiation oncology, pathology, and diagnostic imaging. This multidisciplinary team collaborates and coordinates each step of a patient’s care including diagnosis, evaluation, and treatment. The team provides a complete range of standard treatments, as well as medical and surgical approaches not found anywhere in Connecticut.
Our team is composed of surgeons with extensive clinical experience and fellowship training in urologic oncology from the nation’s most prestigious training programs. Our team has expertise in laparoscopic and robotic surgery, as well as traditional open surgery. Patients who need radiation therapy as a component of their prescribed treatment can feel confident that they are receiving the highest quality care from the most experienced team of radiation oncologists in the state. Working in parallel with the multi-disciplinary team are our pathologists, who are renowned in their field and across the Smilow Cancer Hospital. Our medical oncology team has pioneered numerous treatments for patients with advanced cancers, including the discovery of the first truly effective treatment for metastatic prostate cancer.
Our patients also benefit from specialized resources at Smilow Cancer Hospital such as the newest imaging technologies and have access to caregivers who help them cope with the physical, emotional, and psychological issues related to these cancers, including a health educator, social worker, dietitian, and a complementary alternative medicine program.
Among the comprehensive cutting edge capabilities available through the program are:
- Experience and knowledge in state-of-the-art treatment options and investigational therapies
- Coordinated access to necessary physicians and specialized resources within Yale Cancer Center and Smilow Cancer Hospital
- Urologic medical oncology expertise
- Urologic laparoscopic and robotic surgery expertise, including nerve-sparing robotic prostatectomy and robotic partial nephrectomy
- National and international experience using chemotherapy and hormonal therapy in localized and advanced disease
- Cutting edge radiation therapy technology, including 3D-CRT and IMRT
- State-of-the-art diagnostic imaging - CT and MRI
- Urologic expertise within every specialty
- Comprehensive diagnosis and care for hereditary kidney cancer
- Clinical trials for patients with advanced prostate, bladder, and kidney cancer
Assistant Professor of Urology; Vice Chair of Quality & Safety, Department of Urology; Medical Director, Corporate Supply Chain; Clinical Vice Chair, Department of Urology
Professor of Medicine (Medical Oncology) and of Urology; Co-Leader, Cancer Signaling Networks, Yale Cancer Center
Professor of Urology; Chair, Department of Urology, Yale School of Medicine; Chief, Department of Urology, Yale New Haven Hospital, Urology; Chief Innovation and Transformation Officer, Yale New Haven Health System, Yale New Haven Health System; Faculty Director, Tsai Center for Innovative Thinking at Yale; Co-Founder, Center for Biomedical Innovation and Technology
Associate Professor of Urology; Division Chief, Division of Urology at VA Connecticut Healthcare System; Director, Urology Research Fellowship; Director, Urologic Oncology Clinical Fellowship Program
